“We are assuming equipment is going to be flat for the year.”

In context

“You know, with the biotech guide, it's 6% for the year. I think you guys talked about Discovery Medical flat. That gets us to bioprocess growth, I think, around 6%, which is a bit lower than what I think you guys did in '25. So is that math correct? I'm just wondering, would that imply, like, a bit of a slowdown that you're starting the year at for consumables? Given equipment is stronger? I know, Matt, you talked about conservatism. But this is such a focus. I just want to kind of flush out how you're thinking about the starting point for the '26 guide. Matt McGrew: Yeah. I'm making it very, very clear here. Bioprocessing on the consumable side for the year and for Q1, our assumptions are that will grow high single digits. It's probably going to be at the upper end of high single digits. We are assuming equipment is going to be flat for the year. Bioprocessing will be all up all in high single digits for the year. I think what you're probably referring to is if you look at bioprocessing, the statement, you've got discovery and medical in there as well. I think Discovery and Medical for Q1 we've kind of said it's going to be flat. It might be up a bit. I think the rest of the year for discovery and medical is going to be flat, maybe down a little. To kind of balance that out, you're going to have high single digits out of bioprocessing. No change whatsoever to what we've seen in the end markets and no change to what we have been talking about for a while now. I think, really, the wild card is what does DNM do for the segment. But just to be perfectly clear, we are not seeing any sort of change or slowdown in bioprocess. Dan Brennan”